Following this opinion and in order to further evaluate the safety of those three substances the interested business operators committed to provide further data that would allow a thorough assessment of the in vivo aneugenicity for these three substances [IOFI EFFA Letter DG Sante – EFSA Opinion 216 Rev2 (EFSA Journal (2022; 20(8) 7420)) – follow-up IOFI/EFFA letter: confirmation of follow-up testing and anticipated timings. Ares(2022)8489668].
Recital 7, Regulation (EU) 2024/238
In forcesince 15 Jan 2024